49 results about "Cervical lymph nodes" patented technology

With the goal of creating a combination vaccine against Shigella and other diarrheal pathogens we have constructed a prototype vaccine strain of Shigella flexneri 2a (SC608) that can serve as a vector for the expression and delivery of heterologous antigens to the mucosal immune system. SC608 is an asd derivative of SC602, a well-characterized vaccine strain, which has recently undergone several phase 1 and 2 trials for safety and immunogenicity. Using non-antibiotic asd-based plasmids, we have created novel constructs for the expression of antigens from enterotoxigenic E. coli (ETEC), including CFA / I (CfaB and CfaE) and the B-subunit from heat-labile enterotoxin (LTB) in Shigella vaccine strain SC608. Heterologous protein expression levels and cellular localization are critical to immune recognition and have been verified by immunoblot analysis. Following intranasal immunization (SC608(CFAI) and SC608(CFAI / LTB) of guinea pigs, serum IgG and IgA immune responses to both the Shigella LPS and ETEC antigens can be detected by ELISA. In addition, ELISPOT analysis for ASCs from cervical lymph nodes and spleen showed similar responses. All vaccine strains conferred high levels of protection against challenge with wild-type S. flexneri 2a using the Sereny test. Furthermore, serum from guinea pigs immunized with SC608 expressing CfaB and LTB contained antibodies capable of neutralizing the cytological affects of heat-labile toxin (HLT) on Chinese Hamster Ovary (CHO) cells. These initial experiments demonstrate the validity of a multivalent invasive Shigella strain that can serve as a vector for the delivery of pathogen-derived antigens.

The invention discloses a medicine capable of treating tuberculosis and osteomyelitis. A preparation method of the medicine comprises the steps of grinding baked dinodon rufozonatum, baked centipede, astragalus membranaceus, angelica sinensis, scutellaria baicalensis, dangshen, bighead atractylodes rhizome, angelica dahurica, radix stemonae, honeysuckle, radix rehmanniae, liquorice, radix cyathulae and poria cocos into fine powder, mixing, and refining into pills by using honey. The medicine has an obvious treatment effect on pulmonary tuberculosis, pleurisy, osteoarticular tuberculosis, tuberculosis of cervical lymph nodes, osteomyelitis and the like. After the tuberculosis of cervical lymph nodes ruptures, a thread covered with dinodon rufozonatum powder is inserted into the tuberculosis of cervical lymph nodes, and the medicine has internal and external treatment effects; after sinus tracts form in an osteomyelitis patient, the thread covered with the dinodon rufozonatum powder is inserted into the tracts, fester can be quickly discharged, sequestrum automatically comes off, and osteotrauma automatically repairs to recovery. The medicine does not increase the surgery pain of patients, has no side effects and does not cause serious allergy or damage internal organs after long-term taking; the medicine only needs to be taken at home, and holed cauterized needling can be applied in small clinics, so that the medicine expenses are small. The curative ratio of the tuberculosis diseases is above 99%, and the curative ratio of the osteomyelitis is above 90%.

With the goal of creating a combination vaccine against Shigella and other diarrheal pathogens we have constructed a prototype vaccine strain of Shigella flexneri 2a (SC608) that can serve as a vector for the expression and delivery of heterologous antigens to the mucosal immune system. SC608 is an asd derivative of SC602, a well-characterized vaccine strain, which has recently undergone several phase 1 and 2 trials for safety and immunogenicity. Using non-antibiotic asd-based plasmids, we have created novel constructs for the expression of antigens from enterotoxigenic E. coli (ETEC), including CFA / I (CfaB and CfaE) and the B-subunit from heat-labile enterotoxin (LTB) in Shigella vaccine strain SC608. Heterologous protein expression levels and cellular localization are critical to immune recognition and have been verified by immunoblot analysis. Following intranasal immunization (SC608(CFAI) and SC608(CFAI / LTB) of guinea pigs, serum IgG and IgA immune responses to both the Shigella LPS and ETEC antigens can be detected by ELISA. In addition, ELISPOT analysis for ASCs from cervical lymph nodes and spleen showed similar responses. All vaccine strains conferred high levels of protection against challenge with wild-type S. flexneri 2a using the Sereny test. Furthermore, serum from guinea pigs immunized with SC608 expressing CfaB and LTB contained antibodies capable of neutralizing the cytological affects of heat-labile toxin (HLT) on Chinese Hamster Ovary (CHO) cells. These initial experiments demonstrate the validity of a multivalent invasive Shigella strain that can serve as a vector for the delivery of pathogen-derived antigens.

The invention relates to the technical field of medical detection, in particular to a marker for thyroid cancer diagnosis, stratification and prognosis and application of the marker. The invention provides a marker for cervical lymph node metastasis of thyroid cancer. The marker comprises N-carbohydrate chain markers A2LF, A3F0L, A2F0L and A2F0GL. The expression quantity of the N-carbohydrate chain marker provided by the invention has obvious difference between a thyroid cancer patient with neck lymph node metastasis and a thyroid cancer patient without neck lymph node metastasis, can be used for judging the neck lymph node metastasis of the thyroid cancer, and has relatively high specificity, sensitivity and accuracy.

The invention relates to a vascular targeting embolism sustained release agent of a triple compound microsphere for an antituberculosis drug, a preparation method and applications thereof. The sustained release agent comprises a carrier and a drug, wherein the drug is encapsulated by the carrier, the carrier is selected from sodium alginate or chitosan, and the drug is a triple compound antituberculosis drug which comprises rifampin, isoniazide and pyrazinamide or moxifloxacin. Three antituberculosis drugs are employed as matrixes of a drug solution, sodium alginate or chitosan is used as a carrier solution, and a prepared solution is obtained by mixing the drug solution and the carrier solution. A polymer solution having the drug is enabled to be dispersed into droplets with certain particle sizes and to be sprayed into a curing liquid through a method of high voltage electrostatic droplets, and thus the microsphere for the antituberculosis drug are prepared in the presence of calcium ions. The embolism sustained release agent can be used in the drug for treating pulmonary tuberculosis, pulmonary tuberculosis massive hemoptysis, cavitary pulmonary tuberculosis, renal tuberculosis, osteoarticular tuberculosis, genital tubercolosis, thyroid tuberculosis, tuberculosis of cervical lymph nodes, pericardial tuberculosis, chest-wall tuberculosis and other in-vivo tuberculosises.

The invention discloses a Chinese herbal medicine for treating tuberculosis of cervical lymph nodes. The Chinese herbal medicine is prepared from the following medicines in parts by weight: 10-20 parts of Japanese metaplexis, 10-20 parts of semiliquidambar cathayensis, 40-60 parts of humata repens roots, 20-30 parts of herba chloranthi serrati, 20-30 parts of ixora chinensis and 20-30 parts of barbed skullcap herb. The Chinese herbal medicine is prepared by adding 1000 parts by weight of water, after the water is boiled, decocting the medicines with slow fire for 20-30 minutes, filtering the decoction and collecting the supernatant, decocting the supernatant three times, bottling and uniformly mixing the supernatant decocted three times and then sterilizing the supernatant under a high temperature for later use. The compatibility thought is as follows: Japanese metaplexis is taken as the monarch, semiliquidambar cathayensis and humata repens roots are taken as the ministers, herba chloranthi serrati and ixora chinensis are taken as the assistants, and barbed skullcap herb is taken as the guide. The Chinese herbal medicine has the following beneficial effects: the Chinese herbal medicine is convenient to prepare and use, is safe, does not have side effects, eliminates phlegm and cools blood, has an obvious effect on treating tuberculosis of cervical lymph nodes and has the function of treating both the secondary and primary symptoms.

The invention discloses a traditional Chinese medicine preparation for treating enlargement of cervical lymph nodes after respiratory tract infection in children. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 28-32g of dandelion, 28-32g of wild chrysanthemum flower, 28-32g of cottonrose hibiscus leaf, 28-32g of oldenlandia diffusa, 13-17g of scutellaria baicalensis, 8-12g of flos carthami, 8-12g of radix angelicae dahuricae, 18-22g of gardenia, 3-7g of rheum officinale and 0.3-0.7g of borneol. The selected medicinal materials for the traditional Chinese medicine preparation are appropriate in compatibility, and conform with the research theories of the traditional Chinese medicine and the modern medicine, so that the traditional Chinese medicine preparation has the characteristics of being short in treatment cycle, convenient to use, free of pain, free of a toxic or side effect, fast in acting, low in cost and the like. Through clinical verification, the recovery rate can be up to 96%; the curative effect is good; and the traditional Chinese medicine preparation only needs to be attached to the swollen lymph part of a patient, so that the traditional Chinese medicine preparation can be popularized and applied.

The invention discloses a medicine for treating tuberculosis of cervical lymph nodes, cyclomastopathy and mumps. The medicine is prepared by using the following raw materials by weight part: 4-5 parts of Chinese alangium leaves, 5-8 parts of omoto nipponlily roots, 8-10 parts of rumex madaio, 4-5 parts of Paris rhizomes, 8-10 parts of pokeberry roots, 4-5 parts of radix semiaquilegiae, 8-10 parts of dysosma versipellis and 3-4 parts of toads. A preparation method for the medicine provided by the invention comprises the following steps: weighting all the raw materials by weight part, washing the raw materials and then drying at the temperature below 35 DEG C; milling the raw materials into fine powder and screening by using a 100 mesh sieve; adding 60%-70% alcohol into the powder, wherein the weight of the alcohol is 3-4 times of the total weight of the powder; mixing and soaking for 5-7 days; removing the alcohol; and adding a suitable amount of honey and preparing into paste for externally applying. The medicine provided by the invention has the advantages that only few medicines are externally applied; the pains of a patient caused by taking medicines, injection and surgery are avoided; the application scope is wide; and the medicine is easily absorbed, quickly becomes effective, is high in cure rate, is low in cost and is free from side effect.

The invention relates to the technical field of medical detection, in particular to markers for diagnosis, stratification and prognosis of thyroid cancer and applications thereof. The present invention provides markers for thyroid nodules, which include a combination of one or more of the following N-sugar chain markers: CFa, A2Fa, A4G, A4S, A4FOS, A4L, A4E, A4FOE. The present invention also provides a marker for thyroid cancer, which includes a combination of one or more of the following N-sugar chain markers: CFa, A2Fa, A2L, A2GL. The expression levels of the N-sugar chain markers provided by the present invention are significantly different among healthy people, thyroid nodules, thyroid cancer and patients with cervical lymph node metastasis of thyroid cancer, and can be used for the diagnosis of thyroid nodules and the discrimination of benign and evil thyroid tumors , The discrimination of cervical lymph node metastasis of thyroid cancer has high specificity, sensitivity and accuracy.

The invention relates to a method for selecting features of ultrasound images of cervical lymph nodes, which relates to the technical field of image processing; the technical problem to be solved is to avoid the problem that the selection of features of ultrasound images of cervical lymph nodes by using a genetic algorithm and a discrete particle swarm optimization algorithm is easy to fall into a local extremum; The technical scheme adopted is as follows: the first step is to collect and extract the quantitative features of cervical lymph node images; the second step is to form a sample set; the third step is to design an extreme learning machine classifier; the fourth step is to learn and analyze the sample set Training; the fifth step, calculate the acceleration of each individual Step 6. Update their respective speeds The seventh step is to calculate the respective Boltzmann functions Step 8. Update their respective positions The ninth step, if the termination condition is met, then end and output the optimal position, that is, the optimal feature subset, otherwise the number of iterations is increased by 1, and return to the third step to continue the evolution of the population until the termination condition is met; the present invention is suitable for helping doctors select effective Value of ultrasound image features of cervical lymph nodes.

The invention provides a biological marker of oral cavity oropharynx squamous-cell carcinoma and application of the biological marker. The biological marker is GPD1L and / or HIF1 alpha, and especially a combination of the GPD1L and the alpha. According to the invention, by detecting expression levels of the GPD1L and / or the HIF1 alpha, oral cavity oropharynx squamous-cell carcinoma auxiliary diagnosis, oral cavity oropharynx squamous-cell carcinoma patient prognosis, and / or prognosis cervical lymph node metastasis prediction can be performed.

The present invention proposes miRNA biomarkers and detection kits for the diagnosis of cervical lymph node metastasis of papillary thyroid carcinoma, the miRNAs are hsa-miR-146b, hsa-miR-25-3p, hsa-miR-296- 5p, hsa-miR-222-3p, hsa-miR-21 and hsa-miR-95 combination; detection kit comprising primers capable of amplifying said miRNA biomarkers and probes capable of detecting said miRNA biomarkers . The six miRNAs of the present invention are stably expressed in serum, and they are combined as biomarkers for the diagnosis of lateral cervical lymph node metastasis of thyroid cancer, and the sensitivity and specificity of the diagnosis are significantly higher than those of a single miRNA. The present invention uses serum miRNA to diagnose cervical lymph node metastasis in patients with papillary thyroid carcinoma. Compared with traditional pathological biopsy, the invention has less trauma and is suitable for preoperative diagnosis of patients who are difficult to perform lymph node puncture due to anatomical location and other reasons. , and can be repeated during patient follow-up.